ETF Holdings Breakdown of ORIC

Stock Name	Oric Pharmaceuticals Inc
Ticker	ORIC(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US68622P1093
LEI	54930033FJRNEYBW0L25

ORIC institutional holdings

The following institutional investment holdings of ORIC have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-17 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 11,039 USD 141,078

2025-10-17 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 61,040 USD 780,091

2025-10-17 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 61,040 USD 780,091

Total = 133,119 USD 1,701,260
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	11,039	USD 141,078
2025-10-17	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	61,040	USD 780,091
2025-10-17	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	61,040	USD 780,091
Total =	133,119	USD 1,701,260

News associated with ORIC

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of “Moderate Buy” from Analysts: Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has received an average rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price target […] - 2025-09-19 03:15:02
Brokerages Set Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $17.63: Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month […] - 2025-08-28 03:12:47
JPMorgan Chase & Co. Has Lowered Expectations for Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price: Oric Pharmaceuticals (NASDAQ:ORIC – Free Report) had its price target decreased by JPMorgan Chase & Co. from $20.00 to $17.00 in a research report sent to investors on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. ORIC has been the subject of a number of other reports. Oppenheimer lowered […] - 2025-08-15 04:52:49
Victory Capital Management Inc. Has $838,000 Position in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC): Victory Capital Management Inc. raised its holdings in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 54.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 150,260 shares of the company’s stock after buying an additional 52,760 shares during the period. Victory Capital Management Inc.’s […] - 2025-08-01 05:01:17
Arizona State Retirement System Purchases New Position in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC): Arizona State Retirement System purchased a new stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) during the first quarter, Holdings Channel reports. The institutional investor purchased 10,088 shares of the company’s stock, valued at approximately $56,000. A number of other hedge funds have also modified their holdings of ORIC. Vanguard Group Inc. increased its […] - 2025-07-24 04:38:53
LADENBURG THALM/SH SH Initiates Coverage on Oric Pharmaceuticals (NASDAQ:ORIC): LADENBURG THALM/SH SH assumed coverage on shares of Oric Pharmaceuticals (NASDAQ:ORIC – Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $15.00 price target on the stock. Several other equities research analysts have also recently weighed in on ORIC. Oppenheimer decreased their price objective on Oric […] - 2025-07-11 02:36:47
Brokerages Set Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $19.17: Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have received an average rating of “Buy” from the nine brokerages that are covering the stock, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the stock […] - 2025-07-09 02:33:02
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up After Insider Buying Activity: Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) shares gapped up prior to trading on Tuesday following insider buying activity. The stock had previously closed at $10.00, but opened at $10.63. Oric Pharmaceuticals shares last traded at $10.87, with a volume of 484,723 shares. Specifically, Director Angie You acquired 26,597 shares of the firm’s stock […] - 2025-06-25 02:22:47
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 54.5% during the fourth quarter, Holdings Channel reports. The fund owned 35,579 shares of the company’s stock after purchasing an additional 12,545 shares during the quarter. UBS AM a […] - 2025-06-13 04:32:47
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of “Buy” by Analysts: Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have been assigned an average rating of “Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have covered the stock […] - 2025-06-11 03:08:48
Thursday's ETF Movers: XBI, URA: In trading on Thursday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 1.9% on the day. Components of that ETF showing particular strength include shares of Oric Pharmaceuticals, up about 33.8% and shares of Replimune Group, up about 9.6% on the day. And un - 2025-05-29 12:59:01
Janus Henderson Group PLC Makes New Investment in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC): Janus Henderson Group PLC acquired a new stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 14,600 shares of the company’s stock, valued at approximately $118,000. Several other institutional investors have also recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a […] - 2025-05-26 04:51:01
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $19.17: Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have been assigned an average rating of “Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have updated their coverage on […] - 2025-05-22 05:30:55
Tower Research Capital LLC TRC Purchases 13,384 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC): Tower Research Capital LLC TRC lifted its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 1,048.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,661 shares of the company’s stock after purchasing an additional 13,384 shares during the quarter. […] - 2025-05-09 05:21:00
MetLife Investment Management LLC Purchases 5,530 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC): MetLife Investment Management LLC grew its position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 15.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,608 shares of the company’s stock after acquiring an additional 5,530 shares during the period. MetLife Investment […] - 2025-05-07 05:28:51
HC Wainwright Reiterates Buy Rating for ORIC Pharmaceuticals (NASDAQ:ORIC): ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $21.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 316.67% from the stock’s previous close. Other analysts […] - 2025-05-07 02:58:49
XTX Topco Ltd Has $210,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC): XTX Topco Ltd increased its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 120.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,966 shares of the company’s stock after acquiring an additional 14,209 shares during the period. XTX […] - 2025-04-28 05:11:12
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) PT at $18.86: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has received a consensus recommendation of “Buy” from the nine brokerages that are currently covering the company, Marketbeat reports. Nine research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year […] - 2025-04-25 02:32:47
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Wellington Management Group LLP: Wellington Management Group LLP increased its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 6.9% during the fourth quarter, HoldingsChannel reports. The fund owned 186,430 shares of the company’s stock after buying an additional 12,042 shares during the period. Wellington Management Group LLP’s holdings in ORIC Pharmaceuticals were worth $1,504,000 at […] - 2025-04-14 04:45:06
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.86 Consensus PT from Brokerages: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has been assigned an average rating of “Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have covered the stock in […] - 2025-03-31 02:32:43
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Better-Than-Expected Earnings: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) shares gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $7.85, but opened at $8.57. ORIC Pharmaceuticals shares last traded at $7.99, with a volume of 78,926 shares traded. The company reported ($0.51) EPS for the […] - 2025-02-21 04:56:45
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of “Buy” from Analysts: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has received an average recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in […] - 2025-02-11 06:30:52

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.